This prospective, multi-center, observational study will evaluate the efficacy and the safety of MabThera (rituximab) in patients with rheumatoid arthritis who have not responded or have been intolerant to a first anti-TNF alpha therapy. Patients have commenced MabThera or an alternative anti-TNF alpha treatment as a second biological therapy. Data will be collected for 12 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01592292?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
